Personalized Development of Antisense Oligonucleotides for Exon Skipping Restores Type XVII Collagen Expression in Junctional Epidermolysis Bullosa.

doi:10.3390/ijms22073326

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Personalized Development of Antisense Oligonucleotides for Exon Skipping Restores Type XVII Collagen Expression in Junctional Epidermolysis Bullosa.

International journal of molecular sciences - 24 Mar 2021

Ablinger Michael, Lettner Thomas, Friedl Nicole, Potocki Hannah, Palmetzhofer Theresa, Koller Ulrich, Illmer Julia, Liemberger Bernadette, Hainzl Stefan, Klausegger Alfred, Reisenberger Manuela, Lambert Jo, Van Gele Mireille, Desmet Eline, Van Maelsaeke Els, Wimmer Monika, Zauner Roland, Bauer Johann W, Wally Verena

Abstract excerpt

Intermediate junctional epidermolysis bullosa caused by mutations in the COL17A1 gene is characterized by the frequent development of blisters and erosions on the skin and mucous membranes. The rarity of the disease and the heterogeneity of the underlying mutations renders therapy developments challenging. However, the high number of short in-frame exons facilitates the use of antisense oligonucleotides (AON) to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autoantigens

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Collagen Type XVII

Share to Epidermolysis Bullosa, Junctional

Share to Keratinocytes

Share to Liposomes

Share to Non-Fibrillar Collagens

Share to Oligonucleotides, Antisense

Share to Organ Culture Techniques

Source

Open in PubMed Open full text

Identifiers

PMID: 33805154
DOI: 10.3390/ijms22073326
PMCID: PMC8036626

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Personalized Development of Antisense Oligonucleotides for Exon Skipping Restores Type XVII Collagen Expression in Junctional Epidermolysis Bullosa.PMID 33805154Read ↗

In Vitro Models for the Evaluation of Antisense Oligonucleotides in Skin.Semantic proximity Read ↗

Targeted Exon Skipping Restores Type VII Collagen Expression and Anchoring Fibril Formation in an In Vivo RDEB Model.Semantic proximity Read ↗

Splicing Modulation via Antisense Oligonucleotides in Recessive Dystrophic Epidermolysis BullosaSemantic proximity Read ↗

Splice modulation strategy applied to deep intronic variants in COL7A1 causing recessive dystrophic epidermolysis bullosaSemantic proximity Read ↗

QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study.Semantic proximity Read ↗

COL7A1 Editing via RNA Trans-Splicing in RDEB-Derived Skin Equivalents.Semantic proximity Read ↗

Antisense Oligonucleotide-mediated Exon Skipping as a Systemic Therapeutic Approach for Recessive Dystrophic Epidermolysis BullosaSemantic proximity Read ↗

Therapeutic Prospects of Exon Skipping for Epidermolysis Bullosa.Semantic proximity Read ↗

Antisense-mediated exon skipping to reframe transcripts.Semantic proximity Read ↗

Paired nicking-mediated COL17A1 reframing for junctional epidermolysis bullosa.Semantic proximity Read ↗

Base edited skin equivalents with clinical potential for ex vivo correction of recessive dystrophic epidermolysis bullosa.Semantic proximity Read ↗

Gene Therapy for Dystrophic Epidermolysis Bullosa.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.